Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Breaking New Ground in Oncology: Leonard Mazur from Citius Pharmaceuticals in Conversation with PharmaShots 
Shots:   Citius Pharmaceuticals celebrates its first-ever FDA approval with Lymphir, a novel therapy for relapsed or refractory cutaneous T-cell lymphoma     In an exclusive conversation, Leonard Mazur, Co-Founder and CEO at Citius Pharmaceuticals, shares insights on Lymphir’s launch strategy and its potential impact on the oncology landscape    Leonard also highlights Mino-Lok, Citius’ innovative…
October 6, 2025
Expanding Solid Tumor Care: Shaun Bagai from RenovoRx in a Stimulating Conversation with PharmaShots 
Shots:  RenovoRx, a clinical-stage life sciences company, is developing targeted oncology therapies and has created RenovoCath, an FDA-cleared novel drug delivery device.  Its proprietary TAMP therapy platform enables precise delivery of therapeutics across the arterial wall near the tumor site, directly targeting the tumor while potentially reducing the toxicities linked to systemic IV chemotherapy.  In…
September 29, 2025
Navigating Amorphous Calcium Carbonate Therapies: Eden Ben from Amorphical in Conversation with PharmaShots 
Shots:  ACC therapies introduce a novel treatment approach by modulating local pH, promoting bone remodeling, and reducing inflammation, with potential applications in osteoarthritis, calcium deficiencies, late-stage cancers, and bone disorders.  Amorphical’s AMOR-18 showed encouraging results in an interim Phase II clinical trial involving COVID-19 patients.  PharmaShots speaks with Eden Ben, CEO of Amorphical, to discuss…
September 22, 2025
Pain Management & Beyond: Paul Howe from Protega Pharmaceuticals in a Stimulating Conversation with PharmaShots 
Shots:  Abuse-deterrent products are prescription medications, primarily opioids and certain stimulants, designed to resist common methods of misuse, such as crushing, snorting, or injecting  Protega Pharmaceuticals’ RoxyBond is the first and only FDA-approved, immediate-release abuse-deterrent opioid indicated for managing severe pain when alternative treatments are inadequate  PharmaShots is pleased to feature Paul Howe, Chief Operations…
September 17, 2025
Mehul Desai from Enable Injections in a Riveting Conversation with PharmaShots
Wearable Drug Delivery System: Mehul Desai from Enable Injections in a Riveting Conversation with PharmaShots 
Shots:  Enable Injections recently shared survey findings indicating that many oncology assets with strong commercial potential are often prematurely abandoned or deprioritized due to challenges in formulating small volumes (<3 mL) for subcutaneous delivery.  To address this need, Enable Injections developed enFuse, an innovative, hands-free, wearable drug delivery platform with a discreet, hidden needle that…
September 15, 2025
Joshua Salsi from Biocon Biologics in a Riveting Conversation with PharmaShots
Unlocking Approval: Joshua Salsi from Biocon Biologics in a Riveting Conversation with PharmaShots 
Shots:  The United States has about 38.4 million people living with diabetes, representing 11.6% of the total population. With growing prevalence, there is a significant unmet need for affordable diabetes medications.  Biocon Biologics recently announced the FDA approval of Kirsty, the first and only interchangeable biosimilar to NovoLog (Insulin Aspart).  Joshua Salsi, the Head of…
September 8, 2025
Shawn Opatka from Honeywell in a Riveting Dialogue Exchange with PharmaShots
AI-Mediated Recalls: Shawn Opatka from Honeywell in a Riveting Dialogue Exchange with PharmaShots
Shots:  Product recalls in biopharma and MedTech incur an unanticipated drain on budget, costing the industry between $2.5B to $5B per year on average  Honeywell’s TrackWise Recall Management helps biopharma and MedTech companies plan and execute recall processes seamlessly, contributing to improved patient safety and faster response times  Shawn Opatka, Vice President & General Manager,…
September 1, 2025
Jazz Pharmaceuticals at ASCO 2025: Robert lannone in an Illuminating Conversation with PharmaShots
Jazz Pharmaceuticals at ASCO 2025: Robert lannone in an Illuminating Conversation with PharmaShots
Shots:  Jazz Pharmaceuticals and partners presented seven abstracts from their oncology development program at ASCO 2025   Robert Iannone, EVP, Global Head of Research and Development, and Chief Medical Officer at Jazz Pharmaceuticals, in an engaging discussion with PharmaShots, shared insights from the P-III IMforte trial assessing Zepzelca plus atezolizumab in first-line maintenance treatment for Extensive…
August 25, 2025
Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots
Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots 
Shots:  Fragmented workflows continue to be a major roadblock in the healthcare ecosystem, causing unnecessary delays in care delivery  Automated solutions help bridge the gaps resulting from disjointed workflows and expedite prior authorization, pharmacy routing, and patient onboarding  Colin Banas, CMO at DrFirst, joins PharmaShots in a discussion highlighting the company’s recent acquisition of Myndshft…
August 20, 2025
Load more